Analyst Francois Brisebois of LifeSci Capital maintained a Buy rating on Centessa Pharmaceuticals, retaining the price target of $49.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Francois Brisebois has given his Buy rating due to a combination of factors related to Centessa Pharmaceuticals’ promising developments in the field of sleep disorders. The company’s focus on orexin agonists, particularly their candidate ORX750, shows significant potential in treating conditions like narcolepsy and idiopathic hypersomnia. The emerging data on the efficacy and safety of these treatments positions Centessa favorably in a growing market.
Moreover, Centessa’s strategic planning for future studies, such as the ORX750 registrational program and ORX142 patient studies, indicates a strong pipeline that could lead to successful commercialization. Despite the company’s current cash burn rate, their financial position appears sustainable for the next two years, providing a solid foundation for continued research and development. These factors collectively contribute to the Buy rating, reflecting confidence in Centessa’s future growth prospects.
According to TipRanks, Brisebois is an analyst with an average return of -2.2% and a 36.99% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Kala Pharmaceuticals, Praxis Precision Medicines, and Centessa Pharmaceuticals.